import { Link } from 'react-router-dom';
import { SEOHead } from '@/components/seo/SEOHead';
import { HealthcareResearchPageShell } from '@/components/healthcare-research/HealthcareResearchPageShell';
import { HealthcareNavCard, HealthcareStatPanel } from '@/components/healthcare-research/healthcareResearchUi';
import { ReportMidPageCta } from '@/components/report-conversion';
import { ReportPremiumSection } from '@/components/report-premium';
import { getHealthcareMarketResearchLandingConfig } from '@/data/reportConversionConfig';
import { buildBreadcrumbSchema, buildFAQSchema } from '@/lib/seo/schemas';

const canonicalPath = '/diabetes-market-research-uae';

const faqItems = [
  {
    question: 'How large is the UAE diabetes pharmaceutical market and what are the key product categories?',
    answer:
      "The UAE diabetes pharmaceutical market is one of the most commercially significant therapy area markets in the GCC, driven by a national adult diabetes prevalence of approximately 19% (IDF Diabetes Atlas 2023) — among the highest globally, ranking the UAE fourth in the world by age-adjusted adult diabetes prevalence. The total diabetes pharmaceutical market spans insulin (basal, bolus, and premixed analogue insulins), oral antidiabetic agents (metformin, DPP-4 inhibitors, SGLT2 inhibitors), GLP-1 receptor agonists (including the rapidly growing semaglutide segment), and newer combination products. Key commercial players include Novo Nordisk (dominant in insulin and GLP-1 agonists with Ozempic, Victoza, Rybelsus, and the insulin portfolio), Sanofi (Lantus, Toujeo, and Soliqua), Eli Lilly (Trulicity, and the insulin Humalog/Basaglar portfolio), AstraZeneca (Bydureon, Farxiga/dapagliflozin — a major SGLT2 inhibitor player), and Merck/MSD (Januvia/sitagliptin — a leading DPP-4 inhibitor). The biosimilar insulin segment is growing, with Indian manufacturers (Biocon/Mylan) and European biosimilar entrants competing on price in the MOH and DHA formulary segments. GLP-1 receptor agonists are experiencing the fastest growth, driven by the dual indication of diabetes management and weight loss — the UAE's high obesity rates amplify this commercial opportunity beyond the diabetes indication alone.",
  },
  {
    question: 'How does the UAE payer landscape specifically affect diabetes drug access?',
    answer:
      'UAE diabetes drug access operates through three distinct formulary channels, each with different coverage criteria and therapeutic substitution policies. The DHA Essential Drug List covers insured Dubai residents: metformin, sulfonylureas, and older insulin formulations are broadly listed; branded GLP-1 agonists and newer branded SGLT2 inhibitors are on the DHA formulary but may require prior authorisation or are restricted to specialist prescribers (endocrinologists or diabetologists) rather than general practitioners. The DOH/Daman Abu Dhabi formulary is similar in structure but historically more conservative on biosimilar insulin substitution: Daman has approved biosimilar insulins for listing but maintains prescriber authority over biologic-biosimilar switching in insulin. The MOHAP National Formulary covers public hospital facilities in the northern emirates and has a more cost-focused formulary committee that tends to prefer generic and biosimilar alternatives over branded originator products wherever bioequivalence is established. For novel, high-cost diabetes agents — such as the fixed-ratio GLP-1/basal insulin combinations or the GLP-1/GIP agonist tirzepatide (Mounjaro, Eli Lilly) — UAE formulary access requires a full payer dossier including clinical evidence of superiority over listed alternatives, budget impact modelling, and payer advisory board validation of the target population definition.',
  },
  {
    question: 'What does treatment pathway research in UAE diabetes reveal about GP versus specialist prescribing dynamics?',
    answer:
      'Treatment pathway research in the UAE diabetes market consistently reveals a complex two-tier prescribing system. General practitioners and family medicine physicians in polyclinic settings manage the majority of newly diagnosed and stable type 2 diabetes patients — particularly in the primary care polyclinic networks that have expanded significantly under both DHA and DOH primary care development programmes. GPs typically initiate treatment with metformin and make first-line oral antidiabetic agent choices. However, treatment intensification decisions — switching to injectable therapy, initiating GLP-1 agonists or SGLT2 inhibitors for cardioprotective or renal-protective indications, or managing poorly controlled patients — are predominantly made by endocrinologists and diabetologists at the specialist level. The GP-to-specialist referral trigger is typically documented HbA1c above 8–9% despite 3–6 months of oral therapy, or the presence of cardiovascular or renal comorbidities that activate the guideline-recommended use of SGLT2 inhibitors or GLP-1 agonists. BioNixus treatment pathway research maps this referral trigger landscape through physician surveys (n=50–100 GPs, n=40–60 endocrinologists) and patient journey IDIs, identifying the specific decision points where commercial intervention has the highest impact.',
  },
  {
    question: 'How does Ramadan fasting affect UAE diabetes research design and patient behaviour findings?',
    answer:
      'Ramadan fasting is a clinically and commercially significant context for diabetes management in the UAE and across GCC markets. An estimated 50–80% of Muslim patients with type 2 diabetes choose to fast during Ramadan despite medical advice, creating a well-documented period of increased clinical risk — hypoglycaemia risk with sulfonylureas and insulin, dehydration risk with SGLT2 inhibitors, and adherence disruption across multiple drug classes. For pharmaceutical market research, Ramadan has three important implications. First, patient journey research must include the Ramadan dimension explicitly: how patients adjust their medication regimens, how physicians advise patients about fasting management, and where the current standard of care is inadequate creates important positioning opportunity for drugs with Ramadan-specific management data (such as basal insulins with low hypoglycaemia risk profiles). Second, HCP research should include Ramadan-specific prescribing decision scenarios: which drugs GPs and endocrinologists prefer for patients who insist on fasting, and what clinical support they use for Ramadan fasting guidance. Third, research timing matters: conducting patient adherence research during Ramadan will capture non-representative behaviour; scheduling studies immediately after Eid to capture the behavioural reflection period is typically more productive for understanding normal treatment adherence patterns.',
  },
  {
    question: 'What is the feasibility of recruiting UAE diabetes patients for qualitative research?',
    answer:
      'Patient recruitment for UAE diabetes qualitative research is feasible but requires careful design for several UAE-specific reasons. The UAE diabetes patient population is approximately 88% expatriate, reflecting the national demographic structure: a large portion of patients are South Asian (Indian, Pakistani, Bangladeshi), Arab (Egyptian, Levantine, Arab expatriate), and East Asian, with a smaller proportion of UAE nationals. This demographic diversity means that Arabic and Urdu/Hindi language IDI and FGD instruments are required alongside English for representative patient recruitment — English-only research will systematically under-represent South Asian patients, who are disproportionately prevalent in the UAE diabetes patient population due to genetic predisposition. UAE national patients (approximately 12% of the diabetes patient population) are typically recruited through DHA or DOH clinical network referral rather than open panel recruitment, as UAE nationals are more likely to be engaged with public healthcare networks and SEHA facilities. Patient recruitment through clinic partnerships — diabetes clinics within SEHA hospitals, DHA polyclinic networks, and major private hospital endocrinology departments — is the most effective channel, typically achieving 70–80% recruitment success from clinic referral compared to 20–30% from panel or social media outreach. A target of 20–30 patient IDIs across 4–6 weeks is achievable through clinic network recruitment for most common diabetes sub-populations.',
  },
  {
    question: 'Is the UAE moving toward outcomes-based pricing for high-cost diabetes drugs?',
    answer:
      'The UAE is at an early but definite stage of movement toward outcomes-based pricing (OBP) for high-cost diabetes products, particularly within the Abu Dhabi DOH and Daman framework. Daman has begun exploring managed-entry agreements for selected high-cost products, and DOH health economics advisors have expressed interest in outcomes-linkage mechanisms for products where real-world outcomes in UAE patients may differ from trial outcomes in predominantly non-UAE populations. For GLP-1 agonists and SGLT2 inhibitors — where the clinical evidence for cardiovascular and renal outcomes is strong in international trial populations but UAE real-world data are limited — a credible OBP framework would require UAE-specific RWE commitments. BioNixus has conducted payer advisory boards in Abu Dhabi in which Daman medical directors explicitly identified outcomes-based access as a preferred model for novel high-cost diabetes agents. For pharmaceutical teams considering UAE access strategy for premium diabetes products, BioNixus recommends including an OBP feasibility assessment as part of payer primary research — specifically probing whether DOH/Daman decision-makers would be open to an outcomes-linkage arrangement and what outcomes metrics they would specify.',
  },
];

const jsonLd = [
  {
    '@context': 'https://schema.org',
    '@type': 'Service',
    name: 'Diabetes Market Research UAE',
    serviceType: 'Diabetes pharmaceutical market research and access strategy in the UAE',
    areaServed: ['United Arab Emirates', 'Dubai', 'Abu Dhabi'],
    provider: {
      '@type': 'Organization',
      name: 'BioNixus',
      url: 'https://www.bionixus.com',
    },
    description:
      'BioNixus delivers diabetes market research in the UAE covering HCP prescribing behaviour, patient journey research, payer landscape analysis, and competitive intelligence across insulin, oral antidiabetics, GLP-1 agonists, and SGLT2 inhibitors.',
  },
  buildBreadcrumbSchema([
    { name: 'Home', href: '/' },
    { name: 'Healthcare Market Research', href: '/healthcare-market-research' },
    { name: 'UAE Pharmaceutical Market Research', href: '/uae-pharmaceutical-market-research' },
    { name: 'Diabetes Market Research UAE', href: canonicalPath },
  ]),
  buildFAQSchema(faqItems),
];

const conversionConfig = getHealthcareMarketResearchLandingConfig(
  'Diabetes market research UAE',
  canonicalPath,
  'United Arab Emirates',
  { showEgyptPhone: false, therapyArea: 'Diabetes' },
);

const faqSectionId = 'diabetes-market-research-uae-faq';

export default function DiabetesMarketResearchUae() {
  return (
    <>
      <SEOHead
        title="Diabetes Market Research UAE | BioNixus"
        description="Diabetes market research UAE: HCP prescribing behaviour, patient journey research, payer landscape analysis, and competitive intelligence across insulin, GLP-1 agonists, and SGLT2 inhibitors. UAE has 19% adult diabetes prevalence — the 4th highest globally."
        canonical={canonicalPath}
        jsonLd={jsonLd}
      />

      <HealthcareResearchPageShell
        progressId="diabetes-market-research-uae"
        config={conversionConfig}
        breadcrumbs={[
          { name: 'Home', href: '/' },
          { name: 'Healthcare Market Research', href: '/healthcare-market-research' },
          { name: 'UAE Pharmaceutical Market Research', href: '/uae-pharmaceutical-market-research' },
          { name: 'Diabetes Market Research UAE', href: canonicalPath },
        ]}
        hero={{
          title: 'Diabetes Market Research UAE',
          countryName: 'United Arab Emirates',
          marketSlug: 'uae',
          therapyName: 'Diabetes',
          therapySlug: 'diabetes',
          badges: ['DHA · DOH · MOHAP', 'Diabetes & cardiometabolic'],
          stats: [
            { value: '~19%', label: 'UAE adult diabetes prevalence (IDF 2023)' },
            { value: '10–14 wks', label: 'Typical multi-method programme timeline' },
            { value: '$75K–$200K', label: 'Comprehensive study cost range' },
          ],
          description: (
            <p>
              The UAE has one of the world&apos;s highest diabetes burdens — approximately 19% adult prevalence — and a
              rapidly evolving pharmaceutical market spanning insulin, GLP-1 agonists, SGLT2 inhibitors, and DPP-4
              inhibitors. BioNixus delivers HCP, patient, and payer research that pharmaceutical teams need to navigate
              UAE diabetes prescribing dynamics, formulary access, and competitive positioning. Start from the{' '}
              <Link to="/healthcare-market-research" className="text-primary font-medium hover:underline">
                healthcare market research hub
              </Link>{' '}
              or the{' '}
              <Link to="/healthcare-market-research/therapy/diabetes" className="text-primary font-medium hover:underline">
                diabetes therapy guide
              </Link>{' '}
              for regional context.
            </p>
          ),
          metaLinks: (
            <div className="flex flex-wrap gap-2 text-sm">
              <Link to="/uae-pharmaceutical-market-research" className="text-primary hover:underline">
                UAE pharmaceutical market research
              </Link>
              <span className="text-muted-foreground">·</span>
              <Link to="/patient-journey-research-gcc" className="text-primary hover:underline">
                Patient journey research GCC
              </Link>
              <span className="text-muted-foreground">·</span>
              <Link to="/uae-market-access-research" className="text-primary hover:underline">
                UAE market access research
              </Link>
            </div>
          ),
        }}
        tocItems={[
          { href: '#key-indicators', label: 'Market indicators' },
          { href: '#market-context', label: 'Commercial context' },
          { href: '#key-players', label: 'Key players' },
          { href: '#treatment-pathways', label: 'Treatment pathways' },
          { href: '#hcp-prescribing', label: 'HCP prescribing' },
          { href: '#patient-journey', label: 'Patient journey' },
          { href: '#payer-research', label: 'Payer research' },
          { href: '#research-design', label: 'Research design' },
          { href: `#${faqSectionId}`, label: 'FAQ' },
        ]}
        faq={{
          sectionId: faqSectionId,
          title: 'Diabetes market research UAE FAQs',
          items: faqItems,
        }}
      >
        <ReportPremiumSection
          id="key-indicators"
          title="UAE diabetes market indicators"
          variant="cream"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <HealthcareStatPanel
            stats={[
              { label: 'UAE adult diabetes prevalence', value: '~19%' },
              { label: 'Global rank (age-adjusted adult prevalence)', value: '4th' },
              { label: 'Programme timeline', value: '10–14 weeks' },
              { label: 'Programme cost range', value: '$75K–$200K' },
            ]}
            caption="IDF Diabetes Atlas 2023. Programme ranges reflect typical multi-method HCP, patient, and payer modules."
          />
        </ReportPremiumSection>

        <ReportPremiumSection
          id="market-context"
          title="UAE diabetes burden and commercial context"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <p>
              The United Arab Emirates faces one of the most severe diabetes burdens of any country globally. According
              to the International Diabetes Federation Diabetes Atlas 2023, approximately 19% of UAE adults have
              diabetes — equivalent to approximately 1.1 million people out of a total adult population of 6.5 million.
              The UAE&apos;s ranking as 4th highest in the world by age-adjusted adult diabetes prevalence reflects the
              confluence of genetic predisposition among the South Asian expatriate workforce, sedentary lifestyle patterns,
              high caloric dietary habits, and the demographic skew toward working-age adults who have been exposed to
              risk factors for a decade or more.
            </p>
            <p>
              The prediabetes burden is equally significant: an estimated additional 17–19% of UAE adults have impaired
              glucose tolerance or impaired fasting glucose, representing a large population at high conversion risk. This
              prediabetes segment is commercially relevant for pharmaceutical companies developing prevention-focused
              pharmacological interventions, as UAE health authorities have launched national diabetes prevention
              programmes that create a policy environment supportive of early pharmacological intervention research.
            </p>
          </div>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="key-players"
          title="Key players in the UAE diabetes pharmaceutical market"
          variant="muted"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <p>
              The UAE diabetes pharmaceutical market is commercially competitive across multiple product segments.
              Understanding the competitive position of each major player is a prerequisite for meaningful market
              research design.
            </p>
            <ul className="list-disc pl-6 space-y-3">
              <li>
                <strong>Novo Nordisk</strong> holds the dominant position in both the insulin market and the GLP-1 agonist
                class (Victoza, Ozempic, Rybelsus). Semaglutide uptake in UAE is driven by dual diabetes and obesity
                indications.
              </li>
              <li>
                <strong>Sanofi</strong> competes through basal insulin (Lantus, Toujeo) and Soliqua, facing increasing
                biosimilar pressure on Lantus in UAE public sector formularies.
              </li>
              <li>
                <strong>Eli Lilly</strong> participates in GLP-1 (Trulicity), insulin (Humalog, Basaglar), and tirzepatide
                (Mounjaro) — the highest-efficacy glucose-lowering agent in UAE as of 2024.
              </li>
              <li>
                <strong>AstraZeneca</strong> leads SGLT2 inhibitors through Farxiga/dapagliflozin with cardiorenal
                benefit indications expanding the prescriber base beyond endocrinology.
              </li>
              <li>
                <strong>Merck/MSD</strong> holds the dominant DPP-4 inhibitor position through Januvia/sitagliptin,
                broadly listed across DHA, DOH, and MOHAP formularies.
              </li>
            </ul>
          </div>
        </ReportPremiumSection>

        <ReportMidPageCta config={conversionConfig} className="my-4" />

        <ReportPremiumSection
          id="treatment-pathways"
          title="Treatment pathway research: GP to specialist referral dynamics"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <p>
              The UAE operates a two-tier diabetes management system: GPs and family medicine physicians manage most
              newly diagnosed and stable type 2 diabetes patients, while endocrinologists handle complex, uncontrolled,
              or complication-heavy cases.
            </p>
            <p>
              Treatment intensification — injectable therapy, GLP-1 or SGLT2 initiation for cardioprotective indications,
              or poorly controlled patients — typically occurs at specialist level. Referral triggers include HbA1c above
              8.5% despite dual oral therapy, cardiovascular or renal comorbidities, or patient preference when injectable
              therapy begins. Many UAE GPs report discomfort initiating GLP-1 agonists, defaulting to DPP-4 or SGLT2
              additions — a commercially relevant GP education gap.
            </p>
          </div>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="hcp-prescribing"
          title="HCP prescribing behaviour: GLP-1 adoption and SGLT2 positioning"
          variant="muted"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <h3 className="text-lg font-semibold text-foreground">GLP-1 adoption barriers</h3>
            <p>
              Despite strong clinical evidence, GLP-1 adoption in UAE faces injection anxiety (especially among South
              Asian patients), cost and reimbursement barriers, specialist-only prescribing restrictions, and
              gastrointestinal tolerability concerns among GPs who have experienced repeated patient refusals.
            </p>
            <h3 className="text-lg font-semibold text-foreground">SGLT2 inhibitor cross-specialty positioning</h3>
            <p>
              SGLT2 inhibitors are increasingly prescribed by cardiologists and nephrologists for cardiorenal
              protective indications independent of glycaemic control. BioNixus HCP research maps this cross-specialty
              dynamic and barriers to SGLT2 initiation by non-endocrinologist specialists.
            </p>
          </div>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="patient-journey"
          title="Patient journey research: adherence barriers and patient experience"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <p>
              Key adherence barriers in UAE diabetes patient research include injection anxiety, Ramadan fasting
              disruption (affecting 70–80% of Muslim patients annually), cost sensitivity for self-pay GLP-1 therapy
              (AED 500–900/month), language and health literacy barriers, and cultural concerns about disease
              disclosure.
            </p>
            <p>
              Patient journey research is typically conducted through 45–60 minute IDIs in Arabic, Hindi/Urdu, or English.
              A target of 20–30 patient IDIs achieves thematic saturation; clinic network recruitment through DHA/DOH
              polyclinics and hospital endocrinology departments typically meets targets within 3–5 weeks.
            </p>
          </div>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="payer-research"
          title="Payer research and health technology assessment context"
          variant="cream"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <p className="text-muted-foreground leading-relaxed">
            UAE payer research for diabetes products must account for DHA, DOH/Daman, and MOHAP evidence requirements.
            DOH Abu Dhabi has begun incorporating outcomes-based access discussions for high-cost diabetes agents. BioNixus
            payer research typically includes 8–12 qualitative interviews with formulary committee members, Daman medical
            directors, DHA formulary committee members, and MOHAP pricing committee representatives.
          </p>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="research-design"
          title="Research design, cost, and timeline"
          countryName="United Arab Emirates"
          marketSlug="uae"
          therapyName="Diabetes"
          therapySlug="diabetes"
        >
          <div className="space-y-4 text-muted-foreground leading-relaxed">
            <p>
              A comprehensive UAE diabetes market study combining quantitative HCP surveys, qualitative patient IDIs,
              and payer interviews runs over <strong>10–14 weeks</strong> and costs between{' '}
              <strong>$75,000 and $200,000</strong> depending on scope.
            </p>
            <ul className="list-disc pl-6 space-y-2">
              <li>
                <strong>Quantitative HCP survey (n=50–100):</strong> $20,000–$40,000 / 4–6 weeks
              </li>
              <li>
                <strong>Qualitative patient IDIs (n=20–30):</strong> $20,000–$35,000 / 4–5 weeks
              </li>
              <li>
                <strong>Payer landscape interviews (n=8–12):</strong> $15,000–$25,000 / 4–5 weeks
              </li>
              <li>
                <strong>Competitive intelligence synthesis:</strong> $10,000–$20,000 / 2–3 weeks
              </li>
              <li>
                <strong>Integrated commercial insights report:</strong> $10,000–$20,000 / 2–3 weeks
              </li>
            </ul>
          </div>
        </ReportPremiumSection>

        <ReportPremiumSection
          id="related-programmes"
          title="Related UAE and GCC research programmes"
          variant="muted"
          countryName="United Arab Emirates"
          marketSlug="uae"
        >
          <div className="grid sm:grid-cols-2 gap-4">
            <HealthcareNavCard
              to="/uae-pharmaceutical-market-research"
              title="UAE pharmaceutical market research"
              description="Emirate-specific DHA, DOH, and MOHAP-aware programmes for launch and access teams."
            />
            <HealthcareNavCard
              to="/patient-journey-research-gcc"
              title="Patient journey research GCC"
              description="Pathway mapping across KSA, UAE, Kuwait, and Qatar for chronic disease programmes."
            />
            <HealthcareNavCard
              to="/uae-market-access-research"
              title="UAE market access research"
              description="Formulary, payer, and pricing intelligence for UAE access decisions."
            />
            <HealthcareNavCard
              to="/uae-pricing-reimbursement-strategy"
              title="UAE pricing and reimbursement strategy"
              description="Pricing and reimbursement modelling aligned to UAE payer realities."
            />
          </div>
        </ReportPremiumSection>
      </HealthcareResearchPageShell>
    </>
  );
}
